# A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted

> **NCT05983874** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **International AIDS Vaccine Initiative** · enrollment: 8 (estimated)

## Conditions studied

- Hiv

## Interventions

- **BIOLOGICAL:** BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage

## Key facts

- **NCT ID:** NCT05983874
- **Lead sponsor:** International AIDS Vaccine Initiative
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-04-16
- **Primary completion:** 2025-03
- **Final completion:** 2025-03
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2024-06-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05983874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05983874, "A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05983874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*